- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacoeconomics of synthetic therapies for multiple sclerosis
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2019-05-15
DOI
10.1080/14656566.2019.1615880
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A new way to estimate neurologic disease prevalence in the United States
- (2019) Lorene M. Nelson et al. NEUROLOGY
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women
- (2018) Nils Koch-Henriksen et al. NEUROLOGY
- Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis
- (2018) Alexander Rae-Grant et al. NEUROLOGY
- Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations
- (2018) Luis Hernandez et al. PHARMACOECONOMICS
- Induction or escalation therapy for patients with multiple sclerosis?
- (2018) E. Le Page et al. REVUE NEUROLOGIQUE
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England
- (2018) Robert Hettle et al. JOURNAL OF MEDICAL ECONOMICS
- Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands
- (2018) M. A. Piena et al. JOURNAL OF MEDICAL ECONOMICS
- The evolution of “No Evidence of Disease Activity” in multiple sclerosis
- (2018) G. Lu et al. Multiple Sclerosis and Related Disorders
- Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
- (2018) Marita Zimmermann et al. CNS DRUGS
- Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia
- (2018) Yen Hoang Le Phan et al. Multiple Sclerosis and Related Disorders
- Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
- (2017) GJ Melendez-Torres et al. HEALTH TECHNOLOGY ASSESSMENT
- Multiple sclerosis: Frequency, cost, and economic burden in the United States
- (2017) Alex Y. Chen et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
- (2017) Tomas Kalincik et al. LANCET NEUROLOGY
- New insights into the burden and costs of multiple sclerosis in Europe
- (2017) Gisela Kobelt et al. Multiple Sclerosis Journal
- Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis
- (2017) David Bargiela et al. NEUROLOGY
- Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies
- (2017) Sergio Iannazzo et al. PHARMACOECONOMICS
- New insights into the burden and costs of multiple sclerosis in Europe
- (2017) Gisela Kobelt et al. Multiple Sclerosis Journal
- Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis
- (2017) Hongbo Yang et al. JOURNAL OF MEDICAL ECONOMICS
- Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States
- (2016) Aseel Bin Sawad et al. CURRENT MEDICAL RESEARCH AND OPINION
- Can new chemical therapies improve the management of multiple sclerosis in children?
- (2016) Emanuele D’Amico et al. EXPERT OPINION ON PHARMACOTHERAPY
- Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study
- (2016) Emanuele D’Amico et al. JOURNAL OF NEUROLOGY
- US health insurance is an obstacle to disease-modifying treatments in MS
- (2016) Dennis Bourdette et al. NEUROLOGY
- Health insurance affects the use of disease-modifying therapy in multiple sclerosis
- (2016) Guoqiao Wang et al. NEUROLOGY
- Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis
- (2016) Luis Hernandez et al. JOURNAL OF MEDICAL ECONOMICS
- The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
- (2016) Wenqing Su et al. JOURNAL OF MEDICAL ECONOMICS
- Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis
- (2016) Emer Fogarty et al. Multiple Sclerosis and Related Disorders
- Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective
- (2016) Julie Chevalier et al. PLoS One
- Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory
- (2016) C. Solaro et al. PLoS One
- Cost of Illness of Multiple Sclerosis - A Systematic Review
- (2016) Olivia Ernstsson et al. PLoS One
- Classification, diagnosis, and differential diagnosis of multiple sclerosis
- (2015) Ilana Katz Sand CURRENT OPINION IN NEUROLOGY
- Progressive multiple sclerosis
- (2015) Daniel Ontaneda et al. CURRENT OPINION IN NEUROLOGY
- Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal
- (2015) Emanuele D’Amico et al. Expert Review of Neurotherapeutics
- Cost of disease-modifying therapies for multiple sclerosis
- (2015) M. G. Brown NEUROLOGY
- The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
- (2015) D. M. Hartung et al. NEUROLOGY
- Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
- (2015) Livio Garattini et al. PHARMACOECONOMICS
- Estimating a Preference-Based Index for an Eight-Dimensional Health State Classification System for Multiple Sclerosis
- (2015) Elizabeth Goodwin et al. VALUE IN HEALTH
- Convergence yet Continued Complexity: A Systematic Review and Critique of Health Economic Models of Relapsing-Remitting Multiple Sclerosis in the United Kingdom
- (2015) Felicity Allen et al. VALUE IN HEALTH
- Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal
- (2015) Emanuele D’Amico et al. Expert Review of Neurotherapeutics
- Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis
- (2015) Dennis Bourdette et al. JAMA Neurology
- Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
- (2015) Alberto Gajofatto et al. World Journal of Clinical Cases
- An initial validation of the Italian Mishel Uncertainty Illness Scale (MUIS) for relapsing remitting multiple sclerosis patients
- (2014) Maria Daniela Giammanco et al. NEUROLOGICAL SCIENCES
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches
- (2014) Shien Guo et al. PHARMACOECONOMICS
- Epidemiology and clinical record of multiple sclerosis in selected countries: a systematic review
- (2013) Natalia Niedziela et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Measuring the Global Burden of Disease
- (2013) Christopher J.L. Murray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis
- (2013) Joel P. Thompson et al. PHARMACOECONOMICS
- Using existing data to identify candidate items for a health state classification system in multiple sclerosis
- (2013) Ayse Kuspinar et al. QUALITY OF LIFE RESEARCH
- Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
- (2013) Florian Castrop et al. Neuropsychiatric Disease and Treatment
- Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis
- (2013) Annie Hawton et al. Applied Health Economics and Health Policy
- Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States
- (2012) Feng Pan et al. CLINICAL THERAPEUTICS
- Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis
- (2012) Ali Manouchehrinia et al. Current Neurology and Neuroscience Reports
- Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy
- (2012) Korinna Karampampa et al. Multiple Sclerosis Journal
- Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries
- (2012) Korinna Karampampa et al. Multiple Sclerosis Journal
- Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis
- (2012) Stephanie R. Earnshaw et al. Applied Health Economics and Health Policy
- Potential Health Care Cost Savings Associated With Early Treatment of Multiple Sclerosis Using Disease-Modifying Therapy
- (2011) Suellen M. Curkendall et al. CLINICAL THERAPEUTICS
- Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica
- (2011) C. Tortorella et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Multiple sclerosis in Italy: cost-of-illness study
- (2011) F. Patti et al. NEUROLOGICAL SCIENCES
- The economic burden of Medicare-eligible patients by multiple sclerosis type
- (2011) Daniel M. Gilden et al. VALUE IN HEALTH
- Health outcomes in economic evaluation: the QALY and utilities
- (2010) S. J. Whitehead et al. BRITISH MEDICAL BULLETIN
- The changing demographic pattern of multiple sclerosis epidemiology
- (2010) Nils Koch-Henriksen et al. LANCET NEUROLOGY
- New perspectives in the natural history of multiple sclerosis
- (2010) H. Tremlett et al. NEUROLOGY
- Economic Burden of Multiple Sclerosis
- (2010) Huseyin Naci et al. PHARMACOECONOMICS
- Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transition
- (2010) Slobodan Jankovic et al. Vojnosanitetski Pregled
- Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs
- (2009) Howard G. Birnbaum et al. CURRENT MEDICAL RESEARCH AND OPINION
- Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b
- (2009) Carlo Lazzaro et al. NEUROLOGICAL SCIENCES
- Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
- (2009) Ray Gani et al. PHARMACOECONOMICS
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search